November 12th, 2020 | 10:03 CET
Alibaba, Silver Viper, Saturn Oil & Gas, CureVac: You need to know!
High fluctuation margins are currently being observed on the market. Due to the shift into cyclical stocks, especially tech stocks like Amazon, Alibaba or the Companies benefiting enormously from the Corona pandemic, like ZOOM or TeamViewer, are falling. Here, after a first commute, there are good buying opportunities. Gold and silver stocks should also be added to the watch list. The uncertainty is certainly not over.
time to read: 2 minutes
|
Author:
Stefan Feulner
ISIN:
CA8283341029 , CA80412L1076 , US01609W1027 , NL0015436031
Table of contents:
Author
Stefan Feulner
The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.
Tag cloud
Shares cloud
Chances of share price explosion
The chart of the Canadian oil producer Saturn Oil & Gas is on the verge of breaking out, and this would be fundamentally justified. On the one hand, the Company is profiting from the resurgent oil price. On the other hand, the team around the experienced CEO John Jeffrey is continuously strengthened with top-class people who can master the aggressive acquisition strategy that has been issued. Jean-Pierre Colin, a manager who has advised not only high-ranking politicians but also completed several billion-dollar deals in his 40-year career, has now been brought on board as the top strategy consultant. Colin sold his Eleonor project to Goldcorp Inc. for more than CAD 1 billion, today known as Newmont Corporation.
When comes the boost?
For a long time, the share price of the Calgary-based Company floated in a range between CAD 0.08 and CAD 0.10. With the recent commitment from Colin, a clear turnover with rising prices comes into the share. According to market observers, major acquisitions should be pending soon. If these are announced, the short-sellers are likely to get cold feet. A vital mark at the moment is CAD 0.12.
Use Reset
Following the decision in the US elections and the announcement that a vaccine against the coronavirus may soon be available, the safe havens of gold and silver corrected sharply. However, the problems of enormous government debt and uncertainties are likely to persist. For investors, there is an opportunity to invest in cheap mining stocks. The Canadian exploration Company Silver Viper Minerals Corp. has also been hit hard. After peaking at around CAD 0.85, there has been a significant correction of no less than 50% since September.
Fundamentals on target
Silver Viper Minerals Corp. is a Canadian-based junior explorer focused on precious metals in Sonora, Mexico. The Company currently operates its La Virginia gold-silver project, formerly owned by Pan American Silver Corp. Drilling at La Virginia has identified a gold-silver vein up to 20 metres in diameter. Assessing the underground trend is part of this years drilling program. Positive outlier results from the drilling of 22.6 g/t gold and 1,431 g/t silver were the most significant.
Fresh money provides flexibility
In connection with a financing round from 2019, Silver Viper is now able to generate a further inflow of funds of around CAD 2.8 million. The financing included an early conversion right of the warrants as soon as the share price trades at an average of at least CAD 0.70 for ten consecutive days. This was achieved in September. CEO Steve Cope intends to use the new money to test other drill-ready anomalies, in addition to existing projects, that the Company has identified on the surface during the sampling program. The Chairman anticipates further momentum that could further increase the value of the Company this year.
In the shadow of BioNTech
Somewhat less noticed than the competitor from Mainz is the Tübingen Company CureVac. The share remains at EUR 51.40, roughly the same level as in mid-August. The Company, financed by Dietmar Hopp, is only marginally behind the conglomerate of BioNTech and Pfizer. The go-ahead for the decisive Phase III tests is to be given this year. CureVac plans to apply for a so-called rolling approval to the European Medicines Agency (EMA) in the first quarter of 2021. If all goes well, the vaccine could be available in mid-2021. Considering that there will be several vaccine suppliers, as the demand is enormous, there is still potential to catch up with the other players when evaluating CureVac.
Conflict of interest
Pursuant to §85 of the German Securities Trading Act (WpHG), we point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH (hereinafter referred to as "Relevant Persons") may in the future hold shares or other financial instruments of the mentioned companies or will bet on rising or falling on rising or falling prices and therefore a conflict of interest may arise in the future. conflict of interest may arise in the future. The Relevant Persons reserve the shares or other financial instruments of the company at any time (hereinafter referred to as the company at any time (hereinafter referred to as a "Transaction"). "Transaction"). Transactions may under certain circumstances influence the respective price of the shares or other financial instruments of the of the Company.
Furthermore, Apaton Finance GmbH reserves the right to enter into future relationships with the company or with third parties in relation to reports on the company. with regard to reports on the company, which are published within the scope of the Apaton Finance GmbH as well as in the social media, on partner sites or in e-mails, on partner sites or in e-mails. The above references to existing conflicts of interest apply apply to all types and forms of publication used by Apaton Finance GmbH uses for publications on companies.
Risk notice
Apaton Finance GmbH offers editors, agencies and companies the opportunity to publish commentaries, interviews, summaries, news and etc. on news.financial. These contents serve information for readers and does not constitute a call to action or recommendations, neither explicitly nor implicitly. implicitly, they are to be understood as an assurance of possible price be understood. The contents do not replace individual professional investment advice and do not constitute an offer to sell the share(s) offer to sell the share(s) or other financial instrument(s) in question, nor is it an nor an invitation to buy or sell such.
The content is expressly not a financial analysis, but rather financial analysis, but rather journalistic or advertising texts. Readers or users who make investment decisions or carry out transactions on the basis decisions or transactions on the basis of the information provided here act completely at their own risk. There is no contractual relationship between between Apaton Finance GmbH and its readers or the users of its offers. users of its offers, as our information only refers to the company and not to the company, but not to the investment decision of the reader or user. or user.
The acquisition of financial instruments entails high risks that can lead to the total loss of the capital invested. The information published by Apaton Finance GmbH and its authors are based on careful research on careful research, nevertheless no liability for financial losses financial losses or a content guarantee for topicality, correctness, adequacy and completeness of the contents offered here. contents offered here. Please also note our Terms of use.
